{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T11:13:45Z","timestamp":1758107625365,"version":"3.44.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s00228-025-03884-w","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:08:58Z","timestamp":1753186138000},"page":"1429-1438","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetics and pharmacometabolomics predictors of clozapine and norclozapine pharmacokinetic exposure in healthy volunteers"],"prefix":"10.1007","volume":"81","author":[{"given":"Orwa","family":"Albitar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohd Rahimi","family":"Muda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siti Maisharah Sheikh","family":"Ghadzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dzul Azri Mohamed","family":"Noor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baharudin","family":"Ibrahim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chin-Hoe","family":"Teh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed Ahmed","family":"Akkaif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimatuzzahra\u2019 Abd","family":"Aziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"3884_CR1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","volume":"174","author":"OD Howes","year":"2017","unstructured":"Howes OD, McCutcheon R, Agid O et al (2017) Treatment-Resistant Schizophrenia: Treatment Response and Resistance in Psychosis (TRRIP) Working Group Consensus Guidelines on Diagnosis and Terminology. Am J Psychiatry 174:216\u2013229. https:\/\/doi.org\/10.1176\/appi.ajp.2016.16050503","journal-title":"Am J Psychiatry"},{"key":"3884_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.3390\/pharmaceutics13081121","volume":"13","author":"O Albitar","year":"2021","unstructured":"Albitar O, Harun SN, Ahmad SNA, Sheikh Ghadzi SM (2021) A Repeated Time-to-Positive Symptoms Improvement among Malaysian Patients with Schizophrenia Spectrum Disorders Treated with Clozapine. Pharmaceutics 13:1121. https:\/\/doi.org\/10.3390\/pharmaceutics13081121","journal-title":"Pharmaceutics"},{"key":"3884_CR3","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","volume":"76","author":"T Masuda","year":"2019","unstructured":"Masuda T, Misawa F, Takase M et al (2019) Association With Hospitalization and All-Cause Discontinuation Among Patients With Schizophrenia on Clozapine vs Other Oral Second-Generation Antipsychotics: A Systematic Review and Meta-analysis of Cohort Studies. JAMA Psychiatry 76:1052\u20131062. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.1702","journal-title":"JAMA Psychiatry"},{"key":"3884_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2020\/9872936","volume":"2020","author":"O Albitar","year":"2020","unstructured":"Albitar O, Harun SN, Zainal H et al (2020) Population Pharmacokinetics of Clozapine: A Systematic Review. Biomed Res Int 2020:1\u201310. https:\/\/doi.org\/10.1155\/2020\/9872936","journal-title":"Biomed Res Int"},{"key":"3884_CR5","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00822.x","volume":"46","author":"G Schaber","year":"1998","unstructured":"Schaber G, Stevens I, Gaertner HJ et al (1998) Pharmacokinetics of clozapine and its metabolites in psychiatric patients: Plasma protein binding and renal clearance. Br J Clin Pharmacol 46:453\u2013459. https:\/\/doi.org\/10.1046\/j.1365-2125.1998.00822.x","journal-title":"Br J Clin Pharmacol"},{"key":"3884_CR6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1192\/BJA.2022.71","volume":"29","author":"RJ Flanagan","year":"2023","unstructured":"Flanagan RJ, Gee S, Belsey S et al (2023) Therapeutic monitoring of plasma clozapine and N-desmethylclozapine (norclozapine): practical considerations. BJPsych Adv 29:92\u2013102. https:\/\/doi.org\/10.1192\/BJA.2022.71","journal-title":"BJPsych Adv"},{"key":"3884_CR7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10928-022-09833-9","volume":"50","author":"O Albitar","year":"2023","unstructured":"Albitar O, Ghadzi SMS, Harun SN et al (2023) Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine. J Pharmacokinet Pharmacodyn 50:21\u201331. https:\/\/doi.org\/10.1007\/s10928-022-09833-9","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"3884_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1055\/s-0031-1286287","volume":"44","author":"C Hiemke","year":"2011","unstructured":"Hiemke C, Baumann P, Bergemann N et al (2011) AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. Pharmacopsychiatry 44:195\u2013235. https:\/\/doi.org\/10.1055\/s-0031-1286287","journal-title":"Pharmacopsychiatry"},{"key":"3884_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/01.jcp.0000106221.36344.4d","volume":"24","author":"A Rostami-Hodjegan","year":"2004","unstructured":"Rostami-Hodjegan A, Amin AM, Spencer EP et al (2004) Influence of Dose, Cigarette Smoking, Age, Sex, and Metabolic Activity on Plasma Clozapine Concentrations. J Clin Psychopharmacol 24:70\u201378. https:\/\/doi.org\/10.1097\/01.jcp.0000106221.36344.4d","journal-title":"J Clin Psychopharmacol"},{"key":"3884_CR10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0006-3223(97)00531-3","volume":"44","author":"PJ Perry","year":"1998","unstructured":"Perry PJ, Bever KA, Arndt S, Combs MD (1998) Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biol Psychiatry 44:733\u2013738. https:\/\/doi.org\/10.1016\/S0006-3223(97)00531-3","journal-title":"Biol Psychiatry"},{"key":"3884_CR11","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","volume":"28","author":"CF Thorn","year":"2018","unstructured":"Thorn CF, M\u00fcller DJ, Altman RB, Klein TE (2018) PharmGKB summary: Clozapine pathway, pharmacokinetics. Pharmacogenet Genomics 28:214\u2013222. https:\/\/doi.org\/10.1097\/FPC.0000000000000347","journal-title":"Pharmacogenet Genomics"},{"key":"3884_CR12","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s40263-024-01092-1","volume":"38","author":"O Albitar","year":"2024","unstructured":"Albitar O, Harun SN, Sheikh Ghadzi SM (2024) Semi-physiological Pharmacokinetic Model of Clozapine and Norclozapine in Healthy, Non-smoking Volunteers: The Impact of Race and Genetics. CNS Drugs 38:571\u2013581. https:\/\/doi.org\/10.1007\/s40263-024-01092-1","journal-title":"CNS Drugs"},{"key":"3884_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/S002280050621","volume":"55","author":"S H\u00e4gg","year":"1999","unstructured":"H\u00e4gg S, Spigset O, Mj\u00f6rndal T et al (1999) Absence of interaction between erythromycin and a single dose of clozapine. Eur J Clin Pharmacol 55:221\u2013226. https:\/\/doi.org\/10.1007\/S002280050621","journal-title":"Eur J Clin Pharmacol"},{"key":"3884_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1046\/j.1365-2125.2000.00111.x","volume":"49","author":"S H\u00e4gg","year":"2000","unstructured":"H\u00e4gg S, Spigset O, Mj\u00f6rndal T, Dahlqvist R (2000) Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 49:59\u201363. https:\/\/doi.org\/10.1046\/j.1365-2125.2000.00111.x","journal-title":"Br J Clin Pharmacol"},{"key":"3884_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/sscp.202100068","volume":"5","author":"O Albitar","year":"2022","unstructured":"Albitar O, Murugaiyah V, Ibrahim B et al (2022) Clozapine and norclozapine monitoring in plasma following surfactant assisted dispersive liquid\u2013liquid microextraction. Sep Sci Plus 5:55\u201364. https:\/\/doi.org\/10.1002\/sscp.202100068","journal-title":"Sep Sci Plus"},{"key":"3884_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1139\/CJPP-2013-0128","volume":"92","author":"S Hamzah","year":"2014","unstructured":"Hamzah S, Teh LK, Siew JSK et al (2014) Pharmacogenotyping of CYP3A5 in predicting dose-adjusted trough levels of tacrolimus among Malaysian kidney-transplant patients. Can J Physiol Pharmacol 92:50\u201357. https:\/\/doi.org\/10.1139\/CJPP-2013-0128","journal-title":"Can J Physiol Pharmacol"},{"key":"3884_CR17","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/J.1365-2710.2007.00822.X","volume":"32","author":"LK Teh","year":"2007","unstructured":"Teh LK, Lee WL, Amir J et al (2007) Single step PCR for detection of allelic variation of MDR1 gene (P-glycoprotein) among three ethnic groups in Malaysia. J Clin Pharm Ther 32:313\u2013319. https:\/\/doi.org\/10.1111\/J.1365-2710.2007.00822.X","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"3884_CR18","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1038\/nprot.2007.376","volume":"211","author":"O Beckonert","year":"2007","unstructured":"Beckonert O, Keun HC, Ebbels TMD et al (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 211(2):2692\u20132703. https:\/\/doi.org\/10.1038\/nprot.2007.376","journal-title":"Nat Protoc"},{"key":"3884_CR19","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/J.EJPS.2018.03.011","volume":"117","author":"AM Amin","year":"2018","unstructured":"Amin AM, Sheau Chin L, Teh CH et al (2018) Pharmacometabolomics analysis of plasma to phenotype clopidogrel high on treatment platelets reactivity in coronary artery disease patients. Eur J Pharm Sci 117:351\u2013361. https:\/\/doi.org\/10.1016\/J.EJPS.2018.03.011","journal-title":"Eur J Pharm Sci"},{"key":"3884_CR20","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1515\/dmpt-2020-0154","volume":"36","author":"F Abd Aziz","year":"2021","unstructured":"Abd Aziz F, Ibrahim B, Murugaiyah V, Sarriff A (2021) Addressing the standardisation of internal standards and preservative used in human bio fluids for NMR analysis: a method optimization. Drug Metab Pers Ther 36:189\u2013197. https:\/\/doi.org\/10.1515\/dmpt-2020-0154","journal-title":"Drug Metab Pers Ther"},{"key":"3884_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/J.JSAT.2017.02.015","volume":"77","author":"H Mostafa","year":"2017","unstructured":"Mostafa H, Amin AM, Teh CH et al (2017) Plasma metabolic biomarkers for discriminating individuals with alcohol use disorders from social drinkers and alcohol-naive subjects. J Subst Abus Treat 77:1\u20135. https:\/\/doi.org\/10.1016\/J.JSAT.2017.02.015","journal-title":"J Subst Abus Treat"},{"key":"3884_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1039\/B907021D","volume":"6","author":"RH Barton","year":"2009","unstructured":"Barton RH, Waterman D, Bonner FW et al (2009) The influence of EDTA and citrateanticoagulant addition to human plasma on information recovery from NMR-based metabolic profiling studies. Mol BioSyst 6:215\u2013224. https:\/\/doi.org\/10.1039\/B907021D","journal-title":"Mol BioSyst"},{"key":"3884_CR23","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/S0278-5846(01)00320-7","volume":"26","author":"E Dailly","year":"2002","unstructured":"Dailly E, Urien S, Chanut E et al (2002) Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance. Prog Neuro-Psychopharmacol Biol Psychiatry 26:699\u2013703. https:\/\/doi.org\/10.1016\/S0278-5846(01)00320-7","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"3884_CR24","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.ejps.2003.09.010","volume":"20","author":"LJA Doude van Troostwijk","year":"2003","unstructured":"Doude van Troostwijk LJA, Koopmans RP, Vermeulen HD, Guchelaar H-J (2003) CYP1A2 activity is an important determinant of clozapine dosage in schizophrenic patients. Eur J Pharm Sci 20:451\u2013457. https:\/\/doi.org\/10.1016\/j.ejps.2003.09.010","journal-title":"Eur J Pharm Sci"},{"key":"3884_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1097\/00008571-200303000-00006","volume":"13","author":"J van der Weide","year":"2003","unstructured":"van der Weide J, Steijns LSW, van Weelden MJ (2003) The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169\u2013172. https:\/\/doi.org\/10.1097\/00008571-200303000-00006","journal-title":"Pharmacogenetics"},{"key":"3884_CR26","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/JCP.0b013e31825ac35c","volume":"32","author":"S-T Lee","year":"2012","unstructured":"Lee S-T, Ryu S, Kim S-R et al (2012) Association Study of 27 Annotated Genes for Clozapine Pharmacogenetics. J Clin Psychopharmacol 32:441\u2013448. https:\/\/doi.org\/10.1097\/JCP.0b013e31825ac35c","journal-title":"J Clin Psychopharmacol"},{"key":"3884_CR27","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1258\/0004563053857798","volume":"42","author":"JE Kootstra-Ros","year":"2005","unstructured":"Kootstra-Ros JE, Smallegoor W, van der Weide J (2005) The cytochrome P450 CYP1A2 genetic polymorphisms *1F and *1D do not affect clozapine clearance in a group of schizophrenic patients. Ann Clin Biochem 42:216\u2013219. https:\/\/doi.org\/10.1258\/0004563053857798","journal-title":"Ann Clin Biochem"},{"key":"3884_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/DDR.21774","volume":"82","author":"A Ortega-V\u00e1zquez","year":"2021","unstructured":"Ortega-V\u00e1zquez A, Mayen-Lobo YG, D\u00e1vila-Ortiz de Montellano DJ et al (2021) Alcohol intake potentiates clozapine adverse effects associated to CYP1A2*1C in patients with refractory psychosis. Drug Dev Res 82:685\u2013694. https:\/\/doi.org\/10.1002\/DDR.21774","journal-title":"Drug Dev Res"},{"key":"3884_CR29","doi-asserted-by":"publisher","unstructured":"Lesche D, Mostafa S, Everall I et al (2019) Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. Pharm J. https:\/\/doi.org\/10.1038\/s41397-019-0108-y","DOI":"10.1038\/s41397-019-0108-y"},{"key":"3884_CR30","doi-asserted-by":"publisher","unstructured":"Olsson E, Edman G, Bertilsson L et al (2015) Genetic and clinical factors affecting plasma clozapine concentration. Prim Care Companion J Clin Psychiatry 17. https:\/\/doi.org\/10.4088\/PCC.14m01704","DOI":"10.4088\/PCC.14m01704"},{"key":"3884_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/JCP.0b013e3181acc372","volume":"29","author":"E Jaquenoud Sirot","year":"2009","unstructured":"Jaquenoud Sirot E, Knezevic B, Morena GP et al (2009) ABCB1 and Cytochrome P450 Polymorphisms. J Clin Psychopharmacol 29:319\u2013326. https:\/\/doi.org\/10.1097\/JCP.0b013e3181acc372","journal-title":"J Clin Psychopharmacol"},{"key":"3884_CR32","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/0269881120946288","volume":"35","author":"F Islam","year":"2021","unstructured":"Islam F, Maciukiewicz M, Freeman N et al (2021) Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine\/N-desmethylclozapine on working memory in schizophrenia. J Psychopharmacol 35:31\u201339. https:\/\/doi.org\/10.1177\/0269881120946288","journal-title":"J Psychopharmacol"},{"key":"3884_CR33","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1111\/bcp.15636","volume":"89","author":"H Alarcan","year":"2023","unstructured":"Alarcan H, Cannet P, Camus V et al (2023) Correlation between assessment of cytochrome P450 1A2 activity and enzyme activity scores, and their relation to clozapine exposure. Br J Clin Pharmacol 89:1665\u20131671. https:\/\/doi.org\/10.1111\/bcp.15636","journal-title":"Br J Clin Pharmacol"},{"key":"3884_CR34","doi-asserted-by":"publisher","first-page":"769","DOI":"10.2217\/PGS.09.22","volume":"10","author":"A Gunes","year":"2009","unstructured":"Gunes A, Ozbey G, Vural EH et al (2009) Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmacogenomics 10:769\u2013778. https:\/\/doi.org\/10.2217\/PGS.09.22","journal-title":"Pharmacogenomics"},{"key":"3884_CR35","doi-asserted-by":"publisher","first-page":"110042","DOI":"10.1016\/J.CBI.2022.110042","volume":"364","author":"E Sang\u00fcesa","year":"2022","unstructured":"Sang\u00fcesa E, Cirujeda C, Concha J et al (2022) Pharmacokinetic interactions between clozapine and valproic acid in patients with treatment-resistant schizophrenia: Does UGT polymorphism affect these drug interactions? Chem Biol Interact 364:110042. https:\/\/doi.org\/10.1016\/J.CBI.2022.110042","journal-title":"Chem Biol Interact"},{"key":"3884_CR36","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/YPG.0000000000000139","volume":"26","author":"H-C Huang","year":"2016","unstructured":"Huang H-C, Lua AC, Wu LS-H et al (2016) Cigarette smoking has a differential effect on the plasma level of clozapine in Taiwanese schizophrenic patients associated with the CYP1A2 gene \u2212163A\/C single nucleotide polymorphism. Psychiatr Genet 26:172\u2013177. https:\/\/doi.org\/10.1097\/YPG.0000000000000139","journal-title":"Psychiatr Genet"},{"key":"3884_CR37","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/BCPT.14009","volume":"134","author":"K Mansour","year":"2024","unstructured":"Mansour K, Ben FN, Ammar H et al (2024) Exploring clozapine pharmacokinetics in Tunisian schizophrenic patients: A population-based modelling approach investigating the impact of genetic and non-genetic variables. Basic Clin Pharmacol Toxicol 134:805\u2013817. https:\/\/doi.org\/10.1111\/BCPT.14009","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"3884_CR38","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/J.BIOPHA.2018.02.038","volume":"100","author":"IS Mohammad","year":"2018","unstructured":"Mohammad IS, He W, Yin L (2018) Understanding of human ATP binding cassette superfamily and novel multidrug resistance modulators to overcome MDR. Biomed Pharmacother 100:335\u2013348. https:\/\/doi.org\/10.1016\/J.BIOPHA.2018.02.038","journal-title":"Biomed Pharmacother"},{"key":"3884_CR39","first-page":"1","volume-title":"Basic and Clinical Pharmacology","author":"BG Katzung","year":"2017","unstructured":"Katzung BG (2017) Introduction: The Nature of Drugs & Drug Development & Regulation. In: Katzung BG (ed) Basic and Clinical Pharmacology, 14th edn. McGraw-Hill, New York, pp 1\u201319","edition":"14"},{"key":"3884_CR40","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/YIC.0000000000000065","volume":"31","author":"A Krivoy","year":"2016","unstructured":"Krivoy A, Gaughran F, Weizman A et al (2016) Gene polymorphisms potentially related to the pharmacokinetics of clozapine. Int Clin Psychopharmacol 31:179\u2013184. https:\/\/doi.org\/10.1097\/YIC.0000000000000065","journal-title":"Int Clin Psychopharmacol"},{"key":"3884_CR41","doi-asserted-by":"publisher","first-page":"235","DOI":"10.2147\/PGPM.S142314","volume":"10","author":"I Piatkov","year":"2017","unstructured":"Piatkov I, Caetano D, Assur Y et al (2017) ABCB1 and ABCC1 single-nucleotide polymorphisms in patients treated with clozapine. Pharmgenomics Pers Med 10:235\u2013242. https:\/\/doi.org\/10.2147\/PGPM.S142314","journal-title":"Pharmgenomics Pers Med"},{"key":"3884_CR42","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.2217\/pgs.09.51","volume":"10","author":"G Consoli","year":"2009","unstructured":"Consoli G, Lastella M, Ciapparelli A et al (2009) ABCB1 polymorphisms are associated with clozapine plasma levels in psychotic patients. Pharmacogenomics 10:1267\u20131276. https:\/\/doi.org\/10.2217\/pgs.09.51","journal-title":"Pharmacogenomics"},{"key":"3884_CR43","doi-asserted-by":"publisher","first-page":"117219","DOI":"10.1016\/J.TAAP.2024.117219","volume":"495","author":"F Ozdemir","year":"2025","unstructured":"Ozdemir F, Oz MD, Tok KC et al (2025) The effects of UGT1A4 and ABCB1 polymorphisms on clozapine and N- desmethyl clozapine plasma levels in Turkish schizophrenia patients. Toxicol Appl Pharmacol 495:117219. https:\/\/doi.org\/10.1016\/J.TAAP.2024.117219","journal-title":"Toxicol Appl Pharmacol"},{"key":"3884_CR44","doi-asserted-by":"publisher","first-page":"442","DOI":"10.47750\/JPTCP.2023.30.11.046","volume":"30","author":"AA Bawadikji","year":"2023","unstructured":"Bawadikji AA, Alshammari MHM, Alenezi BJ et al (2023) The Potential of Pharmacometabonomics and Pharmacogenomics Approach to Determine Clozapine Response among Schizophrenia Patients. J Popul Ther Clin Pharmacol 30:442\u2013451. https:\/\/doi.org\/10.47750\/JPTCP.2023.30.11.046","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"3884_CR45","first-page":"187","volume":"48","author":"IA Gu\u0163iu","year":"2010","unstructured":"Gu\u0163iu IA, Andrie\u015f A, Mircioiu C et al (2010) Pharmacometabonomics, pharmacogenomics and personalized medicine. Rom J Intern Med 48:187\u2013191","journal-title":"Rom J Intern Med"},{"key":"3884_CR46","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/S11306-016-1143-1","volume":"13","author":"V Kantae","year":"2017","unstructured":"Kantae V, Krekels EHJ, Esdonk MJV et al (2017) Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy. Metabolomics 13:9. https:\/\/doi.org\/10.1007\/S11306-016-1143-1","journal-title":"Metabolomics"},{"key":"3884_CR47","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/PSP4.12309","volume":"7","author":"R Kaddurah-Daouk","year":"2018","unstructured":"Kaddurah-Daouk R, Hankemeier T, Scholl EH et al (2018) Pharmacometabolomics Informs About Pharmacokinetic Profile of Methylphenidate. CPT Pharmacometrics Syst Pharmacol 7:525\u2013533. https:\/\/doi.org\/10.1002\/PSP4.12309","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"18","key":"3884_CR48","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1208\/S12248-016-9941-Y","volume":"185","author":"K-H Shin","year":"2016","unstructured":"Shin K-H, Ahn LY, Choi MH et al (2016) Urinary 6\u03b2-Hydroxycortisol\/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach. AAPS J 185(18):1254\u20131261. https:\/\/doi.org\/10.1208\/S12248-016-9941-Y","journal-title":"AAPS J"},{"key":"3884_CR49","doi-asserted-by":"publisher","first-page":"3970","DOI":"10.1021\/ACS.JPROTEOME.5B00440","volume":"14","author":"Q Huang","year":"2015","unstructured":"Huang Q, Aa J, Jia H et al (2015) A Pharmacometabonomic Approach To Predicting Metabolic Phenotypes and Pharmacokinetic Parameters of Atorvastatin in Healthy Volunteers. J Proteome Res 14:3970\u20133981. https:\/\/doi.org\/10.1021\/ACS.JPROTEOME.5B00440","journal-title":"J Proteome Res"},{"key":"3884_CR50","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/JPM14070717","volume":"14","author":"LC Popa","year":"2024","unstructured":"Popa LC, Farcas SS, Andreescu NI (2024) Coffee Consumption and CYP1A2 Polymorphism Involvement in Type 2 Diabetes in a Romanian Population. J Pers Med 14:717. https:\/\/doi.org\/10.3390\/JPM14070717","journal-title":"J Pers Med"},{"key":"3884_CR51","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2133\/DMPK.DMPK-11-RG-054","volume":"26","author":"J Terashima","year":"2011","unstructured":"Terashima J, Habano W, Gamou T, Ozawa S (2011) Induction of CYP1 Family Members under Low-glucose Conditions Requires AhR Expression and Occurs through the Nuclear Translocation of AhR. Drug Metab Pharmacokinet 26:577\u2013583. https:\/\/doi.org\/10.2133\/DMPK.DMPK-11-RG-054","journal-title":"Drug Metab Pharmacokinet"},{"issue":"6","key":"3884_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/srep28178","volume":"61","author":"MD Davidson","year":"2016","unstructured":"Davidson MD, Ballinger KR, Khetani SR (2016) Long-term exposure to abnormal glucose levels alters drug metabolism pathways and insulin sensitivity in primary human hepatocytes. Sci Rep 61(6):1\u201311. https:\/\/doi.org\/10.1038\/srep28178","journal-title":"Sci Rep"},{"key":"3884_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2161-0495.1000233","volume":"5","author":"M Vahabzadeh","year":"2015","unstructured":"Vahabzadeh M, Mohammadpour A-H (2015) Effect of Diabetes Mellitus on the Metabolism of Drugs and Toxins. J Clin Toxicol 5:1\u20138. https:\/\/doi.org\/10.4172\/2161-0495.1000233","journal-title":"J Clin Toxicol"},{"key":"3884_CR54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2165\/00003088-199120060-00004","volume":"20","author":"PR Gwilt","year":"1991","unstructured":"Gwilt PR, Nahhas RR, Tracewell WG (1991) The Effects of Diabetes Mellitus on Pharmacokinetics and Pharmacodynamics in Humans. Clin Pharmacokinet 20:477\u2013490. https:\/\/doi.org\/10.2165\/00003088-199120060-00004","journal-title":"Clin Pharmacokinet"},{"key":"3884_CR55","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1111\/CTS.13394","volume":"15","author":"KE Kvitne","year":"2022","unstructured":"Kvitne KE, \u00c5sberg A, Johnson LK et al (2022) Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity. Clin Transl Sci 15:2685\u20132696. https:\/\/doi.org\/10.1111\/CTS.13394","journal-title":"Clin Transl Sci"},{"key":"3884_CR56","doi-asserted-by":"publisher","first-page":"113056","DOI":"10.1016\/J.JPBA.2019.113056","volume":"180","author":"KM Kamil Gharab","year":"2020","unstructured":"Kamil Gharab KM, Onmaz DE, Abusoglu S et al (2020) The relationship between serum clozapine concentrations and hematological parameters by a validated mass spectrometric method. J Pharm Biomed Anal 180:113056. https:\/\/doi.org\/10.1016\/J.JPBA.2019.113056","journal-title":"J Pharm Biomed Anal"},{"key":"3884_CR57","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/J.SCHRES.2008.12.012","volume":"108","author":"AF Chintoh","year":"2009","unstructured":"Chintoh AF, Mann SW, Lam L et al (2009) Insulin resistance and secretion in vivo: Effects of different antipsychotics in an animal model. Schizophr Res 108:127\u2013133. https:\/\/doi.org\/10.1016\/J.SCHRES.2008.12.012","journal-title":"Schizophr Res"},{"key":"3884_CR58","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/J.EURONEURO.2011.09.003","volume":"22","author":"K Weston-Green","year":"2012","unstructured":"Weston-Green K, Huang XF, Lian J, Deng C (2012) Effects of olanzapine on muscarinic M3 receptor binding density in the brain relates to weight gain, plasma insulin and metabolic hormone levels. Eur Neuropsychopharmacol 22:364\u2013373. https:\/\/doi.org\/10.1016\/J.EURONEURO.2011.09.003","journal-title":"Eur Neuropsychopharmacol"},{"issue":"46","key":"3884_CR59","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41401-024-01401-w","volume":"463","author":"WH Wu","year":"2024","unstructured":"Wu WH, Zhi H, Feng WK et al (2024) Clozapine impaired glucose-stimulated insulin secretion partly by increasing plasma 5-HT levels due to the inhibition of OCT1-mediated hepatic 5-HT uptake in mice. Acta Pharmacol Sin 463(46):687\u2013701. https:\/\/doi.org\/10.1038\/s41401-024-01401-w","journal-title":"Acta Pharmacol Sin"},{"key":"3884_CR60","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5455\/bcp.20120131045705","volume":"22","author":"Y Liu","year":"2012","unstructured":"Liu Y, Li H, Yan M (2012) Individual Differences in The Pharmacokinetics of Clozapine in Healthy Chinese Adults. Bull Clin Psychopharmacol 22:17\u201322. https:\/\/doi.org\/10.5455\/bcp.20120131045705","journal-title":"Bull Clin Psychopharmacol"},{"key":"3884_CR61","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1177\/0091270004266621","volume":"44","author":"C-Y Wang","year":"2004","unstructured":"Wang C-Y, Zhang Z-J, Li W-B et al (2004) The differential effects of steady-state fluvoxamine on the pharmacokinetics of olanzapine and clozapine in healthy volunteers. J Clin Pharmacol 44:785\u2013792. https:\/\/doi.org\/10.1177\/0091270004266621","journal-title":"J Clin Pharmacol"},{"key":"3884_CR62","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1023\/A:1016434312388","volume":"04","author":"MG Choc","year":"1987","unstructured":"Choc MG, Lehr RG, Hsuan F et al (1987) Multiple-Dose Pharmacokinetics of Clozapine in Patients. Pharm Res 04:402\u2013405. https:\/\/doi.org\/10.1023\/A:1016434312388","journal-title":"Pharm Res"},{"key":"3884_CR63","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/FPC.0B013E32834C6EFD","volume":"22","author":"CF Thorn","year":"2012","unstructured":"Thorn CF, Aklillu E, Klein TE, Altman RB (2012) PharmGKB summary: very important pharmacogene information for CYP1A2. Pharmacogenet Genomics 22:73. https:\/\/doi.org\/10.1097\/FPC.0B013E32834C6EFD","journal-title":"Pharmacogenet Genomics"},{"key":"3884_CR64","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S2215-0366(23)00002-0","volume":"10","author":"AF Pardi\u00f1as","year":"2023","unstructured":"Pardi\u00f1as AF, Kappel DB, Roberts M et al (2023) Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. Lancet Psychiatry 10:209\u2013219. https:\/\/doi.org\/10.1016\/S2215-0366(23)00002-0","journal-title":"Lancet Psychiatry"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03884-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03884-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03884-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T06:36:56Z","timestamp":1758091016000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03884-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":64,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["3884"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03884-w","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Human Research Ethics Committee USM, Division of Research & Innovation (R&I), USM Health Campus, Malaysia (USM\/JEPeM\/20090488).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics"}},{"value":"All participants provided written informed consent before enrollment into the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All participants provided written informed consent to publish the study findings prior to enrollment into the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}